ClinicalTrials.gg
RecruitingNCT05841173Updated May 6, 2023

Effects of Weight Loss Management on Cognitive Function in Elderly Women With Obesity

An interventional study of "PanTrek" and Physical Trainings in Obesity and Cognitive Change, sponsored by Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology. Recruiting at 1 site in Russian Federation. Open to female participants aged 60 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2023, 3 years 4 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 3 months after the study started (first participant enrolled Jan 2022, registered Apr 2023).
  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
60 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Obesity with a site in Russian Federation — 3 open to participants now, 4 under way, none of them phase 3. Obesity · Russian Federation.

Planned enrollment
14th of 24
200 · median 220
Started
2022
with 3 others
No phase
9 of 33
2 open now
Registered
27th of 33
by date
Lead sponsor
3 of 33
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology

Among the 33 studies in Obesity with a site in Russian Federation, this one is the 14th largest by planned enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2022, is one of 9 with no phase, and was the 27th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 33 studies in Obesity with a site in Russian Federation are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 60 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Obesity with a site in Russian Federation, or all of them as a file.
02

Study summary

According to studies, the risk of cerebrovascular disease and cognitive decline are associated with age-related changes. In addition, there is data suggesting a relationship between the progression of this pathology and the presence of obesity and associated metabolic disorders. According to to some research, weight loss associated with cognitive function decline. In this regard, the development of effective, applicable in real clinical practice methods of non-drug treatment and prevention of cerebrovascular disorders and age-related cognitive decline in people with obesity and metabolic disorders, who are at high risk, seems to be extremely relevant.

The main goal of the study is to compare the effectiveness of various weight loss approaches and to study their effects on the cognitive functions of elderly obesity women.

Read the detailed description

The high prevalence of comorbid pathology characterised the elderly and senile population. Particularly, comorbid condition is often based on obesity. Also, an important characteristic of the elderly and senile age is the development of age-related cognitive deficit and progressive decline in cognitive functions, that is detected in 60.8% of people over 65 years old in Russia according to the EVKALIPT study.

The prevalence of obesity in the Russian population reaches 40% among the elderly population. According to studies, the presence of obesity is "paradoxically" associated with less progression of cognitive function loss, and the risk reduction in some populations reaches 40%. However, the sarcopenic obesity is an independent predictor of cognitive impairment in the elderly. Consequently, the therapy of obesity in elderly and senile population faces two important aspects: the risk of muscle loss and the development of sarcopenia and progressive cognitive decline. The described features of this age group are consistent with the well-known "obesity paradox", in which overweight and obesity are associated with longer life expectancy.

The risk of muscle mass reduction and cognitive functions decrease determines the formation of a specialised approach to obesity management in older population. Thus, the setting of softer and longer-term goals with a gradual decrease in body weight is typical. Studies have considered the use of various interventions, so far the combination of diet with exercise has proven effectiveness in muscle mass protection. At the same time, regular exercises reliably protect from cognitive decline. Thereby, the combination of diet and physical activity is considered as a suitable approach to obesity management in the elderly.

Recently, there have also been a number of studies evaluating the effectiveness of the ketogenic diet. This diet pattern is reliably effective in body weight reduction, skeletal muscle mass maintenance, and adipose tissue metabolism improvement in the elderly . Also, the neuroprotective effects of the ketogenic diet have been confirmed by meta-analyses and have made it possible to include it in current guidelines for the prevention and treatment of cognitive impairment. However, the high frequency of negative effects and the associated low adherence limit the possibilities of using this diet, which led to the development of exogenous ketones that allow reaching the levels of blood ketone bodies associated with neuroprotective properties (0.2-0.5 mmol/l) with better portability.

The main goal of the study is to compare the effectiveness of various weight loss approaches and to study their effects on the cognitive functions of elderly obesity women.

03

Conditions studied

  • Obesity
  • Cognitive Change

Keywords

  • Elderly
  • Obesity
  • Weight loss
  • Cognitive Change
  • Exogenous Ketones
  • Diet
  • Physical activity
04

Who can participate

Ages eligible
60 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female;
  2. Age 60 and over;
  3. 30.0 kg/m2 or more.

Exclusion criteria

Exclusion Criteria:

  1. Male;
  2. age under 60;
  3. \<30.0 kg/m2;
  4. patients unable or unwilling to comply with the requirements of the protocol, including the signing of (inability to give such consent due to mental deficiency or language barrier), as well as non-compliance with the schedule of visits, persons unable to independently make a decision and sign an informed consent;
  5. less than 6 months after suffering cardiovascular events, stroke, severe surgical interventions and injuries;
  6. alcohol abuse (including chronic pancreatitis of alcoholic etiology) or drug addiction at present or within the last 5 years;
  7. history of malignant diseases, regardless of the treatment during the last 5 years;
  8. less than 4 weeks after suffering acute infectious and / or inflammatory diseases, after the onset of complete clinical and laboratory remission;
  9. pregnancy and lactation;
  10. history of allergic reactions to components of the study product and/or placebo or intolerance to components of the study product and/or placebo.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    The Product Group

    The Product group is prescribed with the investigated product - exogeneous ketone bodies.

    Dietary Supplement: "PanTrek"

  • Active comparator
    The Combined Intervention Group

    The Combined Intervention Group is prescribed with the investigated product -in combination with regular physical trainings.

    Dietary Supplement: "PanTrek" · Behavioral: Physical Trainings

  • Placebo comparator
    The Placebo Group

    The Placebo Group is prescribed with the Placebo.

    Other: Placebo

  • Active comparator
    The Diet Group

    The Diet Group is prescribed with the Diet designed with 500 kcal reduction from daily energy expenditure.

    Behavioral: Diet

  • No intervention
    The Control Group

    The Control Group is prescribed with standard recommendations for weight loss.

Interventions

  • Dietary supplement"PanTrek"

    The intervention is represented by the investigational product "PanTrek", shots with liquid, 25 ml each (TU 10.89.19-01-44850857-2020). The composition of the product "PanTrek" (per 1 dose): * Ginseng dry extract (Panax ginseng Meyer) all parts of the plant - 125 mg (the amount of ginsenosides in one vial is 9.0 mg ± 3.5 mg); * Melissa officinalis dry extract (Melissa officinalis L) all parts of the plant - 340 mg (the amount of hydroxycinnamic acids is 19.50 mg / vial ± 10% in one vial); * Apple juice concentrated 2.5% - 7,5 g; * Potassium beta-hydroxybutyrate - 4,5 g; * Magnesium beta-hydroxybutyrate - 500 mg; * E211 sodium benzoate - no more than 5 mg; * E202 Potassium sorbate - no more than 3,6 mg; * Water purified - up to 25 ml. The product has registered as diet supplement in the Unified Register of Certificates of State Registration N RU.77.99.11.003.R.001152.04.21 from 05.04.2021.

    Also known as: Exogenous ketone bodies

  • BehavioralPhysical Trainings

    Physical activity is represented by 2 workouts lasting 45 minutes per week on an antigravity treadmill Alter-G M320 (AlterG, USA) and 2 sessions of reoxygenation lasting 30 minutes on a normobaric hypoxic therapy device ReOxy (Bitmos GmbH, Germany).

    Also known as: Exercises

  • OtherPlacebo

    The placebo is represented by concentrated apple juice 2.5% - 7.5 g, potassium chloride - 2.405 g, MgCl2 - 0.382 g, sodium benzoate (E211) - 5 mg and potassium sorbate (E202) - 3.6 mg, brought to 25 ml of distilled water.

  • BehavioralDiet

    The studied diet is a low-calorie diet with an average energy value of 1730.16 kcal / day and a certain chemical composition (proteins - 108.80 g / day, fats - 68.10 g / day, carbohydrates - 162.60 g / day), including the main groups products (meat and poultry dishes, fish dishes, dairy products, cereals, vegetables and fruits). On average, 0.96-1.05 g of protein accounted for 1 kg of body weight of the subjects.

06

What researchers measure

Primary outcomes

  1. Change from baseline body weight at 12 weeks

    The dynamics of body weight

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  2. Change from baseline Montreal Cognitive Assessment (MoCa) test scores at 12 weeks

    The changes in the cognitive testing results

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  3. Change from baseline Trail Making Test (TMT) a&b test scores at 12 weeks

    The changes in the cognitive testing results (normal range - less than 78 and 273 seconds (=scores)).

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  4. Change from baseline Word recall test scores at 12 weeks

    The changes in the cognitive testing results (normal range as 45 words (=scores) and more out of 5 repetitions). Minimal - 0 (worse result), maximal score - 50 (excellent result).

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  5. Change from baseline Mean response time in the test "Schulte tables" at 12 weeks

    The changes in the cognitive testing results

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  6. Change from baseline The Stroop Color and Word Test results at 12 weeks

    The changes in the cognitive testing results

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  7. Change from baseline Verbal fluency test results at 12 weeks

    The changes in the cognitive testing results

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

Secondary outcomes

  1. Change from baseline fat mass at 12 weeks

    The changes in the fat mass according to the bioimpedance analysis

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  2. Change from baseline skeletal muscle mass at 12 weeks

    The changes in the skeletal muscle mass according to the bioimpedance analysis

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  3. Change from baseline visceral fat at 12 weeks

    The changes in visceral fat according to the bioimpedance analysis

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  4. Change from baseline total cholesterol serum levels at 12 weeks

    The changes of total cholesterol serum levels

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  5. Change from baseline LDL-cholesterol serum levels at 12 weeks

    The changes of LDL-cholesterol serum levels

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  6. Change from baseline HOMA-IR (homeostasis model assessment - insulin resistance) index at 12 weeks

    The changes of HOMA-IR index

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  7. Change from baseline C-reactive protein (CRP) serum levels at 12 weeks

    The changes of CRP serum levels

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  8. Change from baseline Tumor Necrosis Factor Alpha (TNFa) serum levels at 12 weeks

    The changes of TNFa serum levels

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  9. Change from baseline systolic blood pressure (SBP) at 12 weeks

    The changes of SBP

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  10. Change from baseline diastolic blood pressure (DBP) at 12 weeks

    The changes of DBP

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  11. Change from baseline grip strength at 12 weeks

    The changes of grip strength measured by grip dynamometer on the leading hand

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  12. Change from baseline Six Minute Walk Test distance at 12 weeks

    The changes of Six Minute Walk Test results

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  13. Change from baseline Hamilton Anxiety Rating Scale at 12 weeks

    The changes of Hamilton Anxiety Rating Scale results (normal range - 6 scores and less).

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

  14. Change from baseline Hamilton Depression Rating Scale at 12 weeks

    The changes of Hamilton Depression Rating Scale results (normal range - 7 scores and less).

    Time frame: Baseline (visit 1) and after 12 weeks (visit 2)

07

Study locations

1 of 1 sites recruiting
  • Nutrition Clinic of the Federal Research Centre of Nutrition, Biotechnology and Food Safety
    Moscow, 115446, Russian Federation
    Recruiting
08

References and documents

Publications

  • Dadarlat-Pop A, Sitar-Taut A, Zdrenghea D, Caloian B, Tomoaia R, Pop D, Buzoianu A. Profile of Obesity and Comorbidities in Elderly Patients with Heart Failure. Clin Interv Aging. 2020 Apr 21;15:547-556. doi: 10.2147/CIA.S248158. eCollection 2020. PubMed 32368021 ↗
  • Abdoli N, Salari N, Darvishi N, Jafarpour S, Solaymani M, Mohammadi M, Shohaimi S. The global prevalence of major depressive disorder (MDD) among the elderly: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2022 Jan;132:1067-1073. doi: 10.1016/j.neubiorev.2021.10.041. Epub 2021 Nov 4. PubMed 34742925 ↗
  • Khovasova NO, Vorobyeva NM, Tkacheva ON, Kotovskaya YV, Naumov AV, Selezneva EV, Ovcharova LN. [The prevalence of anemia and its associations with other geriatric syndromes in subjects over 65 years old: data of Russian epidemiological study EVKALIPT]. Ter Arkh. 2022 Jan 15;94(1):24-31. doi: 10.26442/00403660.2022.01.201316. Russian. PubMed 36286917 ↗
  • Martinchik AN, Laikam KE, Kozyreva NA, Keshabyants EE, Mikhailov NA, Baturin AK, Smirnova EA. [The prevalence of obesity in various socio-demographic groups of the population of Russia]. Vopr Pitan. 2021;90(3):67-76. doi: 10.33029/0042-8833-2021-90-3-67-76. Epub 2021 May 17. Russian. PubMed 34264558 ↗
  • Hou Q, Guan Y, Yu W, Liu X, Wu L, Xiao M, Lu Y. Associations between obesity and cognitive impairment in the Chinese elderly: an observational study. Clin Interv Aging. 2019 Feb 15;14:367-373. doi: 10.2147/CIA.S192050. eCollection 2019. PubMed 30863030 ↗
  • Vidyanti AN, Hardhantyo M, Wiratama BS, Prodjohardjono A, Hu CJ. Obesity Is Less Frequently Associated with Cognitive Impairment in Elderly Individuals: A Cross-Sectional Study in Yogyakarta, Indonesia. Nutrients. 2020 Jan 30;12(2):367. doi: 10.3390/nu12020367. PubMed 32019161 ↗
  • Wang H, Hai S, Liu YX, Cao L, Liu Y, Liu P, Yang Y, Dong BR. Associations between Sarcopenic Obesity and Cognitive Impairment in Elderly Chinese Community-Dwelling Individuals. J Nutr Health Aging. 2019;23(1):14-20. doi: 10.1007/s12603-018-1088-3. PubMed 30569063 ↗
  • Colleluori G, Villareal DT. Aging, obesity, sarcopenia and the effect of diet and exercise intervention. Exp Gerontol. 2021 Nov;155:111561. doi: 10.1016/j.exger.2021.111561. Epub 2021 Sep 23. PubMed 34562568 ↗
  • Kokkinidis DG, Armstrong EJ, Giri J. Balancing Weight Loss and Sarcopenia in Elderly Patients With Peripheral Artery Disease. J Am Heart Assoc. 2019 Jul 2;8(13):e013200. doi: 10.1161/JAHA.119.013200. Epub 2019 Jun 29. PubMed 31257976 ↗
  • Giudici KV, Guyonnet S, Rolland Y, Vellas B, de Souto Barreto P, Nourhashemi F; MAPT/DSA Group. Body Weight Variation Patterns as Predictors of Cognitive Decline over a 5 Year Follow-Up among Community-Dwelling Elderly (MAPT Study). Nutrients. 2019 Jun 18;11(6):1371. doi: 10.3390/nu11061371. PubMed 31216732 ↗
  • Bosello O, Vanzo A. Obesity paradox and aging. Eat Weight Disord. 2021 Feb;26(1):27-35. doi: 10.1007/s40519-019-00815-4. Epub 2019 Dec 21. PubMed 31865598 ↗
  • Semlitsch T, Stigler FL, Jeitler K, Horvath K, Siebenhofer A. Management of overweight and obesity in primary care-A systematic overview of international evidence-based guidelines. Obes Rev. 2019 Sep;20(9):1218-1230. doi: 10.1111/obr.12889. Epub 2019 Jul 8. PubMed 31286668 ↗
  • Petroni ML, Caletti MT, Dalle Grave R, Bazzocchi A, Aparisi Gomez MP, Marchesini G. Prevention and Treatment of Sarcopenic Obesity in Women. Nutrients. 2019 Jun 8;11(6):1302. doi: 10.3390/nu11061302. PubMed 31181771 ↗
  • Falck RS, Davis JC, Best JR, Crockett RA, Liu-Ambrose T. Impact of exercise training on physical and cognitive function among older adults: a systematic review and meta-analysis. Neurobiol Aging. 2019 Jul;79:119-130. doi: 10.1016/j.neurobiolaging.2019.03.007. Epub 2019 Mar 26. PubMed 31051329 ↗
  • Ilyas Z, Perna S, A Alalwan T, Zahid MN, Spadaccini D, Gasparri C, Peroni G, Faragli A, Alogna A, La Porta E, Ali Redha A, Negro M, Cerullo G, D'Antona G, Rondanelli M. The Ketogenic Diet: Is It an Answer for Sarcopenic Obesity? Nutrients. 2022 Jan 30;14(3):620. doi: 10.3390/nu14030620. PubMed 35276979 ↗
  • Buckinx F, Aubertin-Leheudre M. Nutrition to Prevent or Treat Cognitive Impairment in Older Adults: A GRADE Recommendation. J Prev Alzheimers Dis. 2021;8(1):110-116. doi: 10.14283/jpad.2020.40. PubMed 33336232 ↗
  • McDonald TJW, Cervenka MC. Lessons learned from recent clinical trials of ketogenic diet therapies in adults. Curr Opin Clin Nutr Metab Care. 2019 Nov;22(6):418-424. doi: 10.1097/MCO.0000000000000596. PubMed 31503023 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Jun 2023, 17 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 17 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2023
First posted
May 3, 2023
StartActual
Jan 9, 2022
Primary completionEst.
Jun 30, 2023
CompletionEst.
Dec 30, 2023
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05841173
Lead sponsor
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology
Collaborators
Federal Stare Budgetary Scientific Institution, Mental Health Research Center
Responsible party
Sponsor
First posted
May 3, 2023
Start date
Jan 9, 2022
Primary completion
Jun 30, 2023 (estimated)
Completion
Dec 30, 2023 (estimated)
Last update
May 6, 2023

Study contacts

Yurgita R. Varaeva, MD, MRes
Contact
YurgitaVaraeva@gmail.com
+79253841894
Antonina V. Starodubova, MD, Full PhD
Contact
avs.ion@yandex.ru
+79167470606
Antonina V. Starodubova, MD, Full PhD
study director · Deputy Director of the Federal Research Centre of Nutrition, Biotechnology and Food Safety
Yurgita R. Varaeva, MD, MRes
principal investigator · Research Fellow of the Federal research Centre of Nutrition, Biotechnology and Food Safety

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion